Retrotope Announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich's Ataxia
September 16, 2016 08:00 ET
|
Retrotope
LOS ALTOS, CA--(Marketwired - Sep 16, 2016) - Dr. Theresa Zesiewicz, principal investigator in Retrotope's first-in-human clinical trial of RT001 in Friedreich's ataxia (FA), today presented early...
US FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Friedreich's Ataxia
June 01, 2016 09:00 ET
|
Retrotope
LOS ALTOS, CA--(Marketwired - Jun 1, 2016) - Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its...
Genelux Appoints George Vandeman and Thomas Zindrick to Board of Directors
May 28, 2014 12:00 ET
|
Genelux
SAN DIEGO, CA--(Marketwired - May 28, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced...
Update: Genelux Corporation Announces Former Amgen and Abbott Executives to Succeed Founder Aladar A. Szalay, Ph.D., as CEO, Chairman of the Board
May 15, 2014 13:17 ET
|
Genelux
SAN DIEGO, CA--(Marketwired - May 15, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today...
Genelux Corporation Announces Former Amgen and Abbott Executives to Succeed Founder Aladar A. Szalay, Ph.D., as CEO, Chairman of the Board
May 12, 2014 10:58 ET
|
Genelux
SAN DIEGO, CA--(Marketwired - May 12, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced...
Genelux Corporation CEO, Dr. Aladar A. Szalay, to Give a Keynote Lecture at the 8th International Conference on Oncolytic Virus Therapeutics
April 08, 2014 11:17 ET
|
Genelux
SAN DIEGO, CA--(Marketwired - Apr 8, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based cancer therapies and diagnostics, today announced that...
Genelux Corporation Appoints John D. Prunty Chief Financial Officer
February 11, 2014 08:00 ET
|
Genelux
SAN DIEGO, CA--(Marketwired - Feb 11, 2014) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, announced today...
FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults
August 13, 2013 13:59 ET
|
Silvergate Pharmaceuticals, Inc.
DENVER, CO--(Marketwired - Aug 13, 2013) - Silvergate Pharmaceuticals Inc. (www.silvergatepharma.com), focused on the development and commercialization of innovative and safe medicines for children,...
Genelux Corporation Appoints Stefan M. Manth, MD, as President & CEO, Genelux Europe
June 27, 2013 08:00 ET
|
Genelux Corporation
SAN DIEGO, CA--(Marketwired - Jun 27, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapeutics and diagnostics, today announced...
Genelux Corporation Presents Abstracts at 2013 ASCO Annual Meeting for Clinical Trials of GL-ONC1, Its Oncolytic Virus Lead Product Candidate
May 30, 2013 07:30 ET
|
Genelux Corporation
SAN DIEGO, CA--(Marketwired - May 30, 2013) - Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and companion diagnostics, today...